US · APLS · BIOTECHNOLOGY
Apellis Pharmaceuticals, Inc. (APLS) intrinsic value and stock valuation
$41.03as of 2026-05-15 · Mkt cap 2.68B
Data updated · price as of 2026-05-15
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Apellis Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values APLS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from APLS’s statements →
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cidara Therapeutics, Inc. (CDTX) $221.38
- Scholar Rock Holding Corporation (SRRK) $44.27
- Kiniksa Pharmaceuticals, Ltd. (KNSA) $44.49
- Beam Therapeutics Inc. (BEAM) $28.46
- Catalyst Pharmaceuticals, Inc. (CPRX) $23.08
- IDEAYA Biosciences, Inc. (IDYA) $32.20
- Adaptive Biotechnologies Corporation (ADPT) $16.02
- Mineralys Therapeutics, Inc. (MLYS) $29.26
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
- CEO
- Cedric Francois
- Employees
- 705
- Beta
- 0.24
Explore
Frequently asked questions
What is the intrinsic value of Apellis Pharmaceuticals, Inc. (APLS)?
InvestorsCraft does not currently publish an intrinsic value for APLS. How the IC value is calculated.
Is APLS undervalued?
InvestorsCraft does not publish an undervaluation signal for APLS at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Aug 19, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.